Leadership Dynamics Recent leadership turnover at the CEO and CFO levels signals a strategic inflection point that could open opportunities for new partnerships, licensing deals, or co-development initiatives.

POD Platform Impel's Precision Olfactory Delivery platform enables pairing with established therapeutics, offering potential for licensing or co-developing additional CNS or other indications with improved delivery.

Growth Readiness As a small commercial-stage company with tens of millions in revenue, Impel could leverage partnerships to scale manufacturing, marketing, and distribution or expand to new geographies and indications.

CNS Focus The focus on CNS diseases and nasal delivery suggests opportunities to partner with pharma players seeking non-oral CNS delivery, enabling co-development of novel therapies using POD.

Partner Ecosystem Past collaborations for patient support and distribution and the IPO background indicate openness to partner-based go-to-market models, channel partnerships, and payer access strategies for faster patient adoption.